DE10233817A1 - Substituierte Diarylheterocyclen, Verfahren zu ihrer Herstellung und ihre Verwendung als Arzneimittel - Google Patents

Substituierte Diarylheterocyclen, Verfahren zu ihrer Herstellung und ihre Verwendung als Arzneimittel Download PDF

Info

Publication number
DE10233817A1
DE10233817A1 DE10233817A DE10233817A DE10233817A1 DE 10233817 A1 DE10233817 A1 DE 10233817A1 DE 10233817 A DE10233817 A DE 10233817A DE 10233817 A DE10233817 A DE 10233817A DE 10233817 A1 DE10233817 A1 DE 10233817A1
Authority
DE
Germany
Prior art keywords
alkyl
aryl
phenyl
independently
compounds according
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
DE10233817A
Other languages
German (de)
English (en)
Inventor
Lothar Dr. Schwink
Siegfried Dr. Stengelin
Matthias Dr. Gossel
Thomas Dr. Boehme
Gerhard Dr. Hessler
Gerard Ph.D. Oro Valley Rosse
Armin Ph.D. Tuscon Walser
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Sanofi Aventis Deutschland GmbH
Original Assignee
Aventis Pharma Deutschland GmbH
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Aventis Pharma Deutschland GmbH filed Critical Aventis Pharma Deutschland GmbH
Priority to DE10233817A priority Critical patent/DE10233817A1/de
Priority to PCT/EP2003/007639 priority patent/WO2004012648A2/de
Priority to AU2003257465A priority patent/AU2003257465A1/en
Priority to BR0312916-0A priority patent/BR0312916A/pt
Priority to PCT/EP2003/007891 priority patent/WO2004011438A1/de
Priority to EP03771060A priority patent/EP1551810B1/de
Priority to AU2003251001A priority patent/AU2003251001B9/en
Priority to JP2004523753A priority patent/JP4568113B2/ja
Priority to AT03771060T priority patent/ATE535513T1/de
Priority to CA002493924A priority patent/CA2493924A1/en
Priority to MXPA05001048A priority patent/MXPA05001048A/es
Priority to PE2003000725A priority patent/PE20040702A1/es
Priority to AR20030102644A priority patent/AR040514A1/es
Priority to MYPI20032759A priority patent/MY142551A/en
Priority to TW092120029A priority patent/TW200408627A/zh
Priority to US10/626,314 priority patent/US7141561B2/en
Publication of DE10233817A1 publication Critical patent/DE10233817A1/de
Priority to IL166471A priority patent/IL166471A/en
Withdrawn legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C07D233/66—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D233/91—Nitro radicals
    • C07D233/92—Nitro radicals attached in position 4 or 5
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/04—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member
    • C07D233/28—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D233/30—Oxygen or sulfur atoms
    • C07D233/32—One oxygen atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C07D233/66—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D233/70—One oxygen atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C07D233/66—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D233/72—Two oxygen atoms, e.g. hydantoin
    • C07D233/74—Two oxygen atoms, e.g. hydantoin with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, attached to other ring members
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C07D233/66—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D233/91—Nitro radicals
    • C07D233/92—Nitro radicals attached in position 4 or 5
    • C07D233/94—Nitro radicals attached in position 4 or 5 with hydrocarbon radicals, substituted by oxygen or sulfur atoms, attached to other ring members
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D243/00—Heterocyclic compounds containing seven-membered rings having two nitrogen atoms as the only ring hetero atoms
    • C07D243/04—Heterocyclic compounds containing seven-membered rings having two nitrogen atoms as the only ring hetero atoms having the nitrogen atoms in positions 1 and 3
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D249/00—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
    • C07D249/02—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms not condensed with other rings
    • C07D249/08—1,2,4-Triazoles; Hydrogenated 1,2,4-triazoles
    • C07D249/10—1,2,4-Triazoles; Hydrogenated 1,2,4-triazoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D249/12—Oxygen or sulfur atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/10—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/10—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/08—Bridged systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/10—Spiro-condensed systems

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Diabetes (AREA)
  • Endocrinology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Child & Adolescent Psychology (AREA)
  • Psychiatry (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Emergency Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Plural Heterocyclic Compounds (AREA)
DE10233817A 2002-07-25 2002-07-25 Substituierte Diarylheterocyclen, Verfahren zu ihrer Herstellung und ihre Verwendung als Arzneimittel Withdrawn DE10233817A1 (de)

Priority Applications (17)

Application Number Priority Date Filing Date Title
DE10233817A DE10233817A1 (de) 2002-07-25 2002-07-25 Substituierte Diarylheterocyclen, Verfahren zu ihrer Herstellung und ihre Verwendung als Arzneimittel
PCT/EP2003/007639 WO2004012648A2 (de) 2002-07-25 2003-07-15 Substituierte diarylheterocyclen, verfahren zu ihrer herstellung und ihre verwendung als arzneimittel
AU2003257465A AU2003257465A1 (en) 2002-07-25 2003-07-15 Substituted diaryl heterocycles, method for the production and use thereof as medicaments
CA002493924A CA2493924A1 (en) 2002-07-25 2003-07-18 Diaryl-substituted cyclic urea derivatives having an mch-modulatory effect
MXPA05001048A MXPA05001048A (es) 2002-07-25 2003-07-18 Derivados de urea ciclica, sustituidos con diarilo que tienen un efecto modulador del mch.
EP03771060A EP1551810B1 (de) 2002-07-25 2003-07-18 Diarylsubstituierte cyclische harnstoffderivate mit mch-modulatorischer wirkung
AU2003251001A AU2003251001B9 (en) 2002-07-25 2003-07-18 Diaryl-substituted cyclic urea derivatives having an MCH-modulatory effect
JP2004523753A JP4568113B2 (ja) 2002-07-25 2003-07-18 Ｍｃｈ調節作用を有するジアリール置換環状尿素誘導体
AT03771060T ATE535513T1 (de) 2002-07-25 2003-07-18 Diarylsubstituierte cyclische harnstoffderivate mit mch-modulatorischer wirkung
BR0312916-0A BR0312916A (pt) 2002-07-25 2003-07-18 Derivados de uréa cìclicos substituìdos por diarila com eficácia moduladora mch
PCT/EP2003/007891 WO2004011438A1 (de) 2002-07-25 2003-07-18 Diarylsubstituierte cyclische harnstoffderivate mit mch-modulatorischer wirkung
PE2003000725A PE20040702A1 (es) 2002-07-25 2003-07-21 Heterociclos diarilicos sustituidos y procedimiento para su preparacion como medicamentos
AR20030102644A AR040514A1 (es) 2002-07-25 2003-07-23 Heterociclos diarilicos sustituidos, procedimiento para la preparacion de medicamentos y la utilizacion de los compuestos para tal fin
MYPI20032759A MY142551A (en) 2002-07-25 2003-07-23 Substituted diaryl heterocycles, process for their preparation and their use as medicaments
TW092120029A TW200408627A (en) 2002-07-25 2003-07-23 Substituted diaryl heterocycles, process for their preparation and their use as medicaments
US10/626,314 US7141561B2 (en) 2002-07-25 2003-07-24 Substituted diaryl heterocycles, process for their preparation and their use as medicaments
IL166471A IL166471A (en) 2002-07-25 2005-01-17 Diaryl-substituted cyclic urea derivatives having an mch-modulatory effect

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
DE10233817A DE10233817A1 (de) 2002-07-25 2002-07-25 Substituierte Diarylheterocyclen, Verfahren zu ihrer Herstellung und ihre Verwendung als Arzneimittel

Publications (1)

Publication Number Publication Date
DE10233817A1 true DE10233817A1 (de) 2004-02-12

Family

ID=30128364

Family Applications (1)

Application Number Title Priority Date Filing Date
DE10233817A Withdrawn DE10233817A1 (de) 2002-07-25 2002-07-25 Substituierte Diarylheterocyclen, Verfahren zu ihrer Herstellung und ihre Verwendung als Arzneimittel

Country Status (14)

Country Link
EP (1) EP1551810B1 (enExample)
JP (1) JP4568113B2 (enExample)
AR (1) AR040514A1 (enExample)
AT (1) ATE535513T1 (enExample)
AU (2) AU2003257465A1 (enExample)
BR (1) BR0312916A (enExample)
CA (1) CA2493924A1 (enExample)
DE (1) DE10233817A1 (enExample)
IL (1) IL166471A (enExample)
MX (1) MXPA05001048A (enExample)
MY (1) MY142551A (enExample)
PE (1) PE20040702A1 (enExample)
TW (1) TW200408627A (enExample)
WO (2) WO2004012648A2 (enExample)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2006015279A1 (en) * 2004-07-28 2006-02-09 Neurogen Corporation Heterocyclic diamine compounds as ligands of the melanin concentrating hormone receptor useful for the treatment of obesity, diabetes, eating and sexual disorders

Families Citing this family (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7241787B2 (en) 2004-01-25 2007-07-10 Sanofi-Aventis Deutschland Gmbh Substituted N-cycloexylimidazolinones, process for their preparation and their use as medicaments
DE102004003811A1 (de) * 2004-01-25 2005-08-11 Aventis Pharma Deutschland Gmbh Substituierte N-Cyclohexylimidazolinone, Verfahren ihrer Herstellung und ihre Verwendung als Arzneimittel
AU2005228986A1 (en) * 2004-03-23 2005-10-13 The Regents Of The University Of California Melanin-concentrating hormone receptor antagonists and methods of use
EP1634598A1 (en) * 2004-09-07 2006-03-15 Laboratorios Del Dr. Esteve, S.A. Use of piperazine derivatives and analogues for the manufacture of a medicament for the prophylaxis and/or treatment of disorders of food ingestion
JP5250967B2 (ja) * 2005-11-30 2013-07-31 三菱化学株式会社 有機化合物、電荷輸送材料、電荷輸送材料用組成物および有機電界発光素子
CN101287713A (zh) 2005-11-30 2008-10-15 三菱化学株式会社 有机化合物、电荷传输材料、电荷传输材料用组合物和有机电致发光元件
EP1966164B1 (en) 2005-12-21 2013-03-06 Janssen Pharmaceutica N.V. Novel substituted pyrazinone derivatives for use in mch-1 mediated diseases
JP2009526794A (ja) * 2006-02-15 2009-07-23 サノフィ−アベンティス 新規なアミノアルコール置換アリールチエノピリミジノン、それらの製造方法及び薬剤としてそれらの使用
BRPI0715160A2 (pt) 2006-08-08 2013-06-11 Sanofi Aventis imidazolidina-2,4-dionas substituÍdas por arilamimoaril-alquil-, processo para preparÁ-las, medicamentos compeendendo estes compostos, e seu uso
ES2483866T3 (es) 2006-12-05 2014-08-08 Janssen Pharmaceutica Nv Derivados de diaza-espiro-piridinona sustituidos novedosos para uso en enfermedades mediadas por MCH-1
US8470841B2 (en) 2008-07-09 2013-06-25 Sanofi Heterocyclic compounds, processes for their preparation, medicaments comprising these compounds, and the use thereof
DE102008049675A1 (de) 2008-09-30 2010-04-01 Markus Dr. Heinrich Verfahren zur Herstellung von 3-Aminobiphenylen
US8410284B2 (en) 2008-10-22 2013-04-02 Merck Sharp & Dohme Corp Cyclic benzimidazole derivatives useful as anti-diabetic agents
US8329914B2 (en) 2008-10-31 2012-12-11 Merck Sharp & Dohme Corp Cyclic benzimidazole derivatives useful as anti-diabetic agents
WO2010068601A1 (en) 2008-12-08 2010-06-17 Sanofi-Aventis A crystalline heteroaromatic fluoroglycoside hydrate, processes for making, methods of use and pharmaceutical compositions thereof
ES2443016T3 (es) 2009-08-26 2014-02-17 Sanofi Nuevos hidratos cristalinos de fluoroglicósidos heteroaromáticos, productos farmacéuticos que comprenden estos compuestos, y su empleo
JP2013520502A (ja) 2010-02-25 2013-06-06 メルク・シャープ・エンド・ドーム・コーポレイション 有用な抗糖尿病薬である新規な環状ベンズイミダゾール誘導体
PH12013501686A1 (en) 2011-02-25 2017-10-25 Merck Sharp & Dohme Novel cyclic azabenzimidazole derivatives useful as anti-diabetic agents
WO2012120052A1 (de) 2011-03-08 2012-09-13 Sanofi Mit carbozyklen oder heterozyklen substituierte oxathiazinderivate, verfahren zu deren herstellung, diese verbindungen enthaltende arzneimittel und deren verwendung
US8710050B2 (en) 2011-03-08 2014-04-29 Sanofi Di and tri- substituted oxathiazine derivatives, method for the production, method for the production thereof, use thereof as medicine and drug containing said derivatives and use thereof
EP2683703B1 (de) 2011-03-08 2015-05-27 Sanofi Neue substituierte phenyl-oxathiazinderivate, verfahren zu deren herstellung, diese verbindungen enthaltende arzneimittel und deren verwendung
EP2683704B1 (de) 2011-03-08 2014-12-17 Sanofi Verzweigte oxathiazinderivate, verfahren zu deren herstellung, ihre verwendung als medikament sowie sie enthaltendes arzneimittel und deren verwendung
EP2683701B1 (de) 2011-03-08 2014-12-24 Sanofi Mit benzyl- oder heteromethylengruppen substituierte oxathiazinderivate, verfahren zu deren herstellung, ihre verwendung als medikament sowie sie enthaltendes arzneimittel und deren verwendung
US8809325B2 (en) 2011-03-08 2014-08-19 Sanofi Benzyl-oxathiazine derivatives substituted with adamantane and noradamantane, medicaments containing said compounds and use thereof
EP2683705B1 (de) 2011-03-08 2015-04-22 Sanofi Di- und trisubstituierte oxathiazinderivate, verfahren zu deren herstellung, ihre verwendung als medikament sowie sie enthaltendes arzneimittel und deren verwendung
US8871758B2 (en) 2011-03-08 2014-10-28 Sanofi Tetrasubstituted oxathiazine derivatives, method for producing them, their use as medicine and drug containing said derivatives and the use thereof
WO2012120050A1 (de) 2011-03-08 2012-09-13 Sanofi Neue substituierte phenyl-oxathiazinderivate, verfahren zu deren herstellung, diese verbindungen enthaltende arzneimittel und deren verwendung
RU2465895C1 (ru) * 2011-09-08 2012-11-10 Государственное образовательное учреждение высшего профессионального образования "Мордовский государственный университет им. Н.П. Огарева" Способ лечения депрессивного невроза
CA2880901A1 (en) 2012-08-02 2014-02-06 Merck Sharp & Dohme Corp. Antidiabetic tricyclic compounds
RU2015140066A (ru) 2013-02-22 2017-03-30 Мерк Шарп И Доум Корп. Противодиабетические бициклические соединения
WO2014139388A1 (en) 2013-03-14 2014-09-18 Merck Sharp & Dohme Corp. Novel indole derivatives useful as anti-diabetic agents
CN105473558B (zh) 2013-06-20 2019-04-19 拜耳作物科学股份公司 作为杀螨剂和杀昆虫剂的芳基硫化物衍生物和芳基硫氧化物衍生物
WO2015051496A1 (en) 2013-10-08 2015-04-16 Merck Sharp & Dohme Corp. Antidiabetic tricyclic compounds
WO2016100823A1 (en) 2014-12-19 2016-06-23 The Broad Institute, Inc. Dopamine d2 receptor ligands
EP3233077A4 (en) 2014-12-19 2018-08-08 The Broad Institute Inc. Dopamine d2 receptor ligands
US11072602B2 (en) 2016-12-06 2021-07-27 Merck Sharp & Dohme Corp. Antidiabetic heterocyclic compounds
WO2018118670A1 (en) 2016-12-20 2018-06-28 Merck Sharp & Dohme Corp. Antidiabetic spirochroman compounds
EP3902805A4 (en) 2018-12-28 2023-03-01 SPV Therapeutics Inc. CYCLINE-DEPENDENT KINASE INHIBITORS

Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0002649A2 (en) * 1977-12-19 1979-06-27 Sandoz Ag 1-Dimethyl-substituted alkyl-2- or 4-substituted phenylimidazoles, their production and their use as anti-obesity agents
EP0503548A1 (de) * 1991-03-12 1992-09-16 Dr. Karl Thomae GmbH Cyclische Harnstoffderivate, diese Verbindungen enthaltende Arzneimittel und Verfahren zu ihrer Herstellung
WO1998058934A1 (fr) * 1997-06-20 1998-12-30 Societe De Conseils De Recherches Et D'applications Scientifiques (S.C.R.A.S.) Nouveaux derives du 2-(iminomethyl)amino-phenyle, leur preparation, leur application a titre de medicaments et les compositions pharmaceutiques les contenant
US6054590A (en) * 1998-03-25 2000-04-25 Bristol-Myers Squibb Company Imidazolone anorectic agents: II. phenyl derivatives
WO2002010141A1 (en) * 2000-07-31 2002-02-07 Pfizer Products Inc. Imidazole derivatives
WO2002051819A2 (en) * 2000-12-26 2002-07-04 Dr. Reddy's Laboratories Ltd. Heterocyclic compounds having antibacterial activity, process for their preparation and pharmaceutical compositions containing them

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1996025410A1 (en) * 1995-02-17 1996-08-22 Takeda Chemical Industries, Ltd. Azole compounds, their production and use
JP2002003370A (ja) * 1999-09-20 2002-01-09 Takeda Chem Ind Ltd メラニン凝集ホルモン拮抗剤
EP1366030A2 (en) * 2000-07-06 2003-12-03 Neurogen Corporation Melanin concentrating hormone receptor ligands
IL153645A0 (en) * 2000-07-31 2003-07-06 Smithkline Beecham Plc Carboxamide compounds and their use as antagonists of a human 11cby receptor
GB0200283D0 (en) * 2002-01-08 2002-02-20 Smithkline Beecham Plc Compounds

Patent Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0002649A2 (en) * 1977-12-19 1979-06-27 Sandoz Ag 1-Dimethyl-substituted alkyl-2- or 4-substituted phenylimidazoles, their production and their use as anti-obesity agents
EP0503548A1 (de) * 1991-03-12 1992-09-16 Dr. Karl Thomae GmbH Cyclische Harnstoffderivate, diese Verbindungen enthaltende Arzneimittel und Verfahren zu ihrer Herstellung
WO1998058934A1 (fr) * 1997-06-20 1998-12-30 Societe De Conseils De Recherches Et D'applications Scientifiques (S.C.R.A.S.) Nouveaux derives du 2-(iminomethyl)amino-phenyle, leur preparation, leur application a titre de medicaments et les compositions pharmaceutiques les contenant
US6054590A (en) * 1998-03-25 2000-04-25 Bristol-Myers Squibb Company Imidazolone anorectic agents: II. phenyl derivatives
WO2002010141A1 (en) * 2000-07-31 2002-02-07 Pfizer Products Inc. Imidazole derivatives
WO2002051819A2 (en) * 2000-12-26 2002-07-04 Dr. Reddy's Laboratories Ltd. Heterocyclic compounds having antibacterial activity, process for their preparation and pharmaceutical compositions containing them

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2006015279A1 (en) * 2004-07-28 2006-02-09 Neurogen Corporation Heterocyclic diamine compounds as ligands of the melanin concentrating hormone receptor useful for the treatment of obesity, diabetes, eating and sexual disorders

Also Published As

Publication number Publication date
IL166471A0 (en) 2006-01-15
MY142551A (en) 2010-12-15
BR0312916A (pt) 2005-06-14
WO2004011438A1 (de) 2004-02-05
AU2003251001B9 (en) 2010-03-04
AU2003251001B2 (en) 2010-01-21
EP1551810B1 (de) 2011-11-30
JP4568113B2 (ja) 2010-10-27
JP2006501202A (ja) 2006-01-12
MXPA05001048A (es) 2005-04-08
AU2003257465A1 (en) 2004-02-23
ATE535513T1 (de) 2011-12-15
EP1551810A1 (de) 2005-07-13
WO2004012648A2 (de) 2004-02-12
PE20040702A1 (es) 2004-11-30
AR040514A1 (es) 2005-04-06
TW200408627A (en) 2004-06-01
CA2493924A1 (en) 2004-02-05
IL166471A (en) 2009-09-01
AU2003251001A1 (en) 2004-02-16

Similar Documents

Publication Publication Date Title
DE10233817A1 (de) Substituierte Diarylheterocyclen, Verfahren zu ihrer Herstellung und ihre Verwendung als Arzneimittel
DE10139416A1 (de) Aminoalkyl substituierte aromatische Bicyclen, Verfahren zu ihrer Herstellung und ihre Verwendung als Arzneimittel
DE602004007693T2 (de) (3-oxo-3,4-dihydro-chinoxalin-2-yl-amino)-benzamid-derivate und verwandte verbindungen als glykogen-phosphorylase-hemmer zur behandlung von diabetes und adipositas
DE69432984T2 (de) Therapeutische substituierte guanidine
DE60315354T2 (de) Pyridazinon-derivate als gsk-3beta-hemmer
DE69418601T2 (de) Guanidinderivate mit therapeutischer wirkung
DE60103927T2 (de) Piperazinderivate, deren Herstellung und deren Verwendung in der Behandlung von Störungen des Zentralnervensystems
DE102004003811A1 (de) Substituierte N-Cyclohexylimidazolinone, Verfahren ihrer Herstellung und ihre Verwendung als Arzneimittel
DE3814549A1 (de) N-substituierte derivate von 1-desoxynojirimycin und 1-desoxymannonojirimycin, verfahren zu deren herstellung und deren verwendung in arzneimitteln
EP0000928A1 (de) Neue Nitroimidazole und diese enthaltende pharmazeutische Präparate sowie deren Herstellung
EP0459256B1 (de) Oxazolidinone mit ZNS-dämpfender Wirkung
DE60114852T2 (de) Chinazolin-derivate als alpha-1 adrenerge antagonisten
DE69317399T2 (de) Aminocycloalkanobenzodioxole als beta-3 selektive adrenergische Wirkstoffe
DE69829215T2 (de) Substituierte beta-alaninen
EP0271013B1 (de) Basisch substituierte Phenylacetonitrile, ihre Herstellung und diese enthaltende Arzneimittel
EP1558583A1 (de) Neue phenylethanolaminderivate und deren verwendung als beta-3-agonisten
DE3010752A1 (de) Substituierte aethanolamine
US20040132752A1 (en) Substituted diaryl heterocycles, process for their preparation and their use as medicaments
DE69911373T2 (de) Azetidincarboxamidderivate zur behandlung von zns-erkrankungen
DE10142663B4 (de) C2-Disubstituierte Indan-1-ol-Systeme
DD271519A5 (de) Verfahren zur herstellung von neuen 1-aryloxy-dihydrobenzothiadiazinylalkylamino-alkanen
CZ20003121A3 (cs) 2-Arylethyl-(piperidin-4-ylmethyl)aminové deriváty jako antagonisty muskarinového receptoru

Legal Events

Date Code Title Description
OP8 Request for examination as to paragraph 44 patent law
8127 New person/name/address of the applicant

Owner name: SANOFI-AVENTIS DEUTSCHLAND GMBH, 65929 FRANKFURT,

8130 Withdrawal